Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Timolol maleate
Drug ID BADD_D02220
Description Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes.[L6724] It is also used in tablet form as a drug to treat hypertension.[L6727] Timolol was first approved by the FDA in 1978.[L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
Indications and Usage Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure.[L6724,L6727] In certain cases, timolol is used in the prevention of migraine headaches.[A179530,L6742]
Marketing Status approved
ATC Code S01ED01; C07AA06
DrugBank ID DB00373
KEGG ID D00603
MeSH ID D013999
PubChem ID 5281056
TTD Drug ID D05UVD
NDC Product Code 82260-812; 82260-819; 11722-076; 49452-7813; 24208-813; 50742-287; 59651-313; 61314-225; 61314-226; 64980-514; 68682-045; 70756-654; 51927-2003; 24208-498; 24208-812; 50090-1852; 60758-801; 68682-812; 68682-813; 70756-656; 54871-1088; 61314-224; 61314-227; 0378-0221; 67877-229; 72485-602; 73152-029; 38779-0366; 51014-7510; 52423-0913; 17478-288; 17478-289; 24208-816; 42571-398; 0187-1498; 82260-045; 17337-0543; 24208-004; 60505-1005; 60758-802; 82260-818; 55545-0440; 64330-014; 45865-121; 0378-0715; 73152-031; 70447-0002; 24208-819; 50090-0558; 0378-0055; 64980-513; 69918-601; 69918-602; 70756-657; 82260-813; 24208-496; 50090-5769; 50742-288; 73152-030; 46014-1059; 24208-814; 0187-1496; 70756-655; 82260-496; 24208-499; 24208-818
UNII P8Y54F701R
Synonyms Timolol | Timolol Maleate | Timolol Maleate, (1:1) Salt | (S)-1-((1,1-Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadazol-3-yl)oxy)-2-propanol | 2-Propanol, 1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-, (S)- | Timoptic | Timoptol | Timacar | Timolol Hemihydrate | Blocadren | L-714,465 | L 714,465 | L714,465 | MK-950 | MK 950 | MK950 | Optimol
Chemical Information
Molecular Formula C17H28N4O7S
CAS Registry Number 60469-65-0
SMILES CC(C)(C)NCC(COC1=NSN=C1N2CCOCC2)O.C(=CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Peripheral coldness23.06.04.008; 24.04.03.006; 08.01.09.010--Not Available
Peyronie's disease21.12.01.002--Not Available
Pruritus23.03.12.001--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pyrexia08.05.02.003--
Rales22.12.01.011--Not Available
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Raynaud's phenomenon24.04.03.003--Not Available
Respiratory distress22.02.01.012--Not Available
Sinoatrial block02.03.01.010--Not Available
Skin irritation23.03.04.009--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Thrombocytopenic purpura01.08.01.003; 23.06.01.007--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Exercise tolerance decreased08.01.03.036--Not Available
Coronary artery insufficiency24.04.04.016; 02.02.01.008--Not Available
Affect lability19.04.01.001--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages